Reports Q1 revenue $, consensus $. “We have made strides in our Phase 1 SB101 trial with established clinical benefit including a 45% reduction ...
PRINCETON - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage biotechnology company specializing in immunotherapy treatments with a current market capitalization of $4.69 million, ...
Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of ...
Hosted on MSN23d
Sonnet BioTherapeutics to expand trial of SON-1010 with trabectedin for solid tumoursThe decision to expand the trial was made following the completion of monotherapy dose escalation for SON-1010.
Love is 'an ever-fixèd mark.' Kate Moncrief and Brendon Fox - No impediments to this marriage of true minds, true love ...
(RTTNews) - Sonnet BioTherapeutics Holdings, Inc. (SONN), a clinical-stage biotechnology company, announced on Tuesday the granting of a new European patent for its Fully Human Albumin Binding or ...
Sonnet's F H AB platform consists of a single, fully human construct of a F H AB antibody fragment that has high affinity to bind to human albumin. The platform provides an off-the-shelf lock and load ...
Sonnet has a new Thunderbolt 5 dock with four TB5 ports and an internal PCIe 4.0 NVMe SSD slot that'll work with your existing M-series Macs and ensure future compatibility with higher speeds.
The upgraded Claude 3.5 Sonnet, the latest and most intelligent model in the Claude model family from artificial intelligence ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback